282 related articles for article (PubMed ID: 16717290)
1. Reimbursement for cancer treatment: coverage of off-label drug indications.
American Society of Clinical Oncology
J Clin Oncol; 2006 Jul; 24(19):3206-8. PubMed ID: 16717290
[TBL] [Abstract][Full Text] [Related]
2. Use and coverage of novel cancer agents in managed care.
Bailes JS
Semin Oncol; 1994 Dec; 21(6 Suppl 14):34-7. PubMed ID: 7992098
[TBL] [Abstract][Full Text] [Related]
3. Antineoplastic agents: comparing off-label uses among authoritative drug compendia.
Thompson DF; Keefe CC
Hosp Formul; 1993 Jul; 28(7):641-2, 647. PubMed ID: 10127046
[TBL] [Abstract][Full Text] [Related]
4. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
5. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
6. Off-label use reimbursement.
Cohen J; Wilson A; Faden L
Food Drug Law J; 2009; 64(2):391-403. PubMed ID: 19999289
[TBL] [Abstract][Full Text] [Related]
7. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience.
Kocs D; Fendrick AM
Am J Manag Care; 2003 May; 9(5):393-400; quiz 401-2. PubMed ID: 12744301
[TBL] [Abstract][Full Text] [Related]
8. Patient care cancer clinical trials at the National Cancer Institute: a resource for payers and providers.
Pearson D
Manag Care Q; 2002; 10(1):33-7. PubMed ID: 15988953
[TBL] [Abstract][Full Text] [Related]
9. TRICARE; off-label uses of devices; partial list of examples of unproven drugs, devices, medical treatments or procedures. Final rule.
Office of the Secretary, Department of Defense (DoD)
Fed Regist; 2012 Jun; 77(124):38177-8. PubMed ID: 22737762
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer.
Mullins CD; Montgomery R; Abernethy AP; Hussain A; Pearson SD; Tunis S;
J Clin Oncol; 2012 Feb; 30(6):661-6. PubMed ID: 22253467
[TBL] [Abstract][Full Text] [Related]
11. Economic aspects of treatment of superficial bladder cancer.
Sudovar S
Urology; 1985 Oct; 26(4 Suppl):57-61. PubMed ID: 3931329
[TBL] [Abstract][Full Text] [Related]
12. The new Medicare bill: far-reaching effects on cancer treatment.
Bailes JS; Coleman T
Clin Adv Hematol Oncol; 2004 May; 2(5):292-4. PubMed ID: 16163195
[TBL] [Abstract][Full Text] [Related]
13. Uses of drugs not described in the package insert (off-label uses).
Committee on Drugs. American Academy of Pediatrics
Pediatrics; 2002 Jul; 110(1 Pt 1):181-3. PubMed ID: 12093968
[TBL] [Abstract][Full Text] [Related]
14. [Off label drug use in adult patients treated by anticancer chemotherapy].
Levêque D; Michallat AC; Schaller C; Ranc M
Bull Cancer; 2005 May; 92(5):498-500. PubMed ID: 15932813
[TBL] [Abstract][Full Text] [Related]
15. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
16. Systematic review: reliability of compendia methods for off-label oncology indications.
Abernethy AP; Raman G; Balk EM; Hammond JM; Orlando LA; Wheeler JL; Lau J; McCrory DC
Ann Intern Med; 2009 Mar; 150(5):336-43. PubMed ID: 19221366
[TBL] [Abstract][Full Text] [Related]
17. Reimbursement policies constrain the practice of oncology.
Laetz T; Silberman G
JAMA; 1991 Dec; 266(21):2996-9. PubMed ID: 1820471
[TBL] [Abstract][Full Text] [Related]
18. Medicare challenges and solutions--reimbursement issues in treating the patient with colorectal cancer.
Kaa K
J Manag Care Pharm; 2007 Aug; 13(6 Suppl C):S19-26. PubMed ID: 17713991
[TBL] [Abstract][Full Text] [Related]
19. Medicare and Medicaid programs; conditions for coverage for end-stage renal disease facilities. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2008 Apr; 73(73):20369-484. PubMed ID: 18464351
[TBL] [Abstract][Full Text] [Related]
20. Reimbursement: current status and future outlook.
Bailes JS
Semin Oncol; 1994 Aug; 21(4 Suppl 7):118-22. PubMed ID: 8091237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
